Skip to main content

Table 4 Base-case cost and outcomes when considering both direct and indirect effects

From: Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

Outcome PCV13 PCV10 Difference(PCV13 – PCV10)
Total life-years 605,602,153 605,586,870 15,283
  Total QALYs 543,278,132 543,264,303 13,828
Annual number of cases
  Myringotomy 1,868 1,918 −49.5
  Neurological impairment 25.7 35. −10.1
  Hearing loss 47.8 66.5 −18.7
  Death 9,601.03 10,480.47 −879.4
  Annual direct medical costs $1,185,354,128 $1,318,177,638 –$132,823,511
Cost per QALY PCV13 dominates PCV10
  1. PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; QALY quality-adjusted life-year.